Memorial Hospital Research Laboratories
The Charles Rudin Lab
Research

Professor
Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.

Featured News
Publications
People

Charles M. Rudin, MD, PhD
Professor
- Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
- MD, PhD, University of Chicago Pritzker School of Medicine
- rudinc@mskcc.org
- Email Address
- View physician profile
- Physician profile
Members




- Residency, Cornell University (Internal Medicine)
- MD, PhD, Columbia University
- BS, Stanford University











Assistant Attending/Lab Co-Director

Senior Research Technician

Research Fellow

Senior Research Assistant/Lab Manager

Thoracic Oncology Fellow

Assistant Attending, Thoracic Oncology Service

Graduate Student

Assistant Attending, Thoracic Oncology Service

Research Fellow

Research Technician

Research Fellow

Research Fellow

Portfolio Manager

Graduate Student

Research Technician

Graduate Student

Graduate Student

- BS, Northeastern University

Lab Alumni

Postdoctoral Research Fellow, Harold Varmus Lab, WCMC

Research Scientist at C4 Therapeutic, Watertown, Massachusetts

Graduate Student

Medical Resident, Yale School of Medicine

Clinician-Scientist, Princess Margaret Cancer Centre and Assistant Professor of Radiation Oncology, University of Toronto

Postdoctoral Research Fellow, Ross Levine Lab, MSKCC
Open Positions
Career Opportunities
Get in Touch
-
Lab Head Email
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Charles M. Rudin discloses the following relationships and financial interests:
-
AbbVie
Provision of Services -
Amgen
Provision of Services (uncompensated) -
Ascentage Pharma
Provision of Services -
Astra Zeneca
Provision of Services -
Bridge Medicines
Provision of Services (uncompensated) -
Celgene
Provision of Services -
Chugai Pharmaceuticals
Provision of Services -
Daiichi Sankyo
Provision of Services
-
Elucida Oncology
Provision of Services (uncompensated) -
Genentech
Provision of Services -
Harpoon Therapeutics, Inc.
Provision of Services -
Loxo Oncology
Provision of Services -
MORE Health, Inc
Provision of Services -
Roche
Provision of Services -
SynDevRx Inc
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.